Cargando…
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280011/ https://www.ncbi.nlm.nih.gov/pubmed/34159559 http://dx.doi.org/10.1007/s12325-021-01815-6 |
| _version_ | 1783722562782494720 |
|---|---|
| author | Perumal, Jai Balabanov, Roumen Su, Ray Chang, Roger Balcer, Laura Galetta, Steven Campagnolo, Denise I. Avila, Robin Lee, Lily Rutledge, Danette Fox, Robert J. |
| author_facet | Perumal, Jai Balabanov, Roumen Su, Ray Chang, Roger Balcer, Laura Galetta, Steven Campagnolo, Denise I. Avila, Robin Lee, Lily Rutledge, Danette Fox, Robert J. |
| author_sort | Perumal, Jai |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8280011 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82800112021-07-20 Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study Perumal, Jai Balabanov, Roumen Su, Ray Chang, Roger Balcer, Laura Galetta, Steven Campagnolo, Denise I. Avila, Robin Lee, Lily Rutledge, Danette Fox, Robert J. Adv Ther Correction Springer Healthcare 2021-06-22 2021 /pmc/articles/PMC8280011/ /pubmed/34159559 http://dx.doi.org/10.1007/s12325-021-01815-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Perumal, Jai Balabanov, Roumen Su, Ray Chang, Roger Balcer, Laura Galetta, Steven Campagnolo, Denise I. Avila, Robin Lee, Lily Rutledge, Danette Fox, Robert J. Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study |
| title | Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study |
| title_full | Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study |
| title_fullStr | Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study |
| title_full_unstemmed | Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study |
| title_short | Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study |
| title_sort | correction to: natalizumab in early relapsing-remitting multiple sclerosis: a 4-year, open-label study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280011/ https://www.ncbi.nlm.nih.gov/pubmed/34159559 http://dx.doi.org/10.1007/s12325-021-01815-6 |
| work_keys_str_mv | AT perumaljai correctiontonatalizumabinearlyrelapsingremittingmultiplesclerosisa4yearopenlabelstudy AT balabanovroumen correctiontonatalizumabinearlyrelapsingremittingmultiplesclerosisa4yearopenlabelstudy AT suray correctiontonatalizumabinearlyrelapsingremittingmultiplesclerosisa4yearopenlabelstudy AT changroger correctiontonatalizumabinearlyrelapsingremittingmultiplesclerosisa4yearopenlabelstudy AT balcerlaura correctiontonatalizumabinearlyrelapsingremittingmultiplesclerosisa4yearopenlabelstudy AT galettasteven correctiontonatalizumabinearlyrelapsingremittingmultiplesclerosisa4yearopenlabelstudy AT campagnolodenisei correctiontonatalizumabinearlyrelapsingremittingmultiplesclerosisa4yearopenlabelstudy AT avilarobin correctiontonatalizumabinearlyrelapsingremittingmultiplesclerosisa4yearopenlabelstudy AT leelily correctiontonatalizumabinearlyrelapsingremittingmultiplesclerosisa4yearopenlabelstudy AT rutledgedanette correctiontonatalizumabinearlyrelapsingremittingmultiplesclerosisa4yearopenlabelstudy AT foxrobertj correctiontonatalizumabinearlyrelapsingremittingmultiplesclerosisa4yearopenlabelstudy |